Evidence map›Paper›PMID 41677596›Full record

ArticleCells2026

Targeting Bladder Cancer with Inactivated Uropathogenic

Vladimir Yutkin, Naseem Maalouf, Chamutal Gur, Avraham Zini, Gilad Bachrach, Ofer Mandelboim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vladimir YutkinDepartment of Urology, Hadassah Hebrew University Medical School, Jerusalem 91120, Israel.
Naseem MaaloufThe Institute of Dental Sciences, The Hebrew University-Hadassah School of Dental Medicine, Jerusalem 91120, Israel.
Chamutal GurThe Concern Foundation Laboratories, The Lautenberg Center for Immunology and Cancer Research, Hebrew University Hadassah Medical School (IMRIC), Jerusalem 91120, Israel.
Avraham ZiniThe Institute of Dental Sciences, The Hebrew University-Hadassah School of Dental Medicine, Jerusalem 91120, Israel.
Gilad BachrachThe Institute of Dental Sciences, The Hebrew University-Hadassah School of Dental Medicine, Jerusalem 91120, Israel.ORCID 0000-0003-1350-2280
Ofer MandelboimThe Concern Foundation Laboratories, The Lautenberg Center for Immunology and Cancer Research, Hebrew University Hadassah Medical School (IMRIC), Jerusalem 91120, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than 90% of bladder cancers are classified as urothelial carcinomas (UC), with approximately 75% of these cases presenting as non-muscle-invasive bladder cancer (NMIBC). Bacillus Calmette-Guérin (BCG) is the current standard immunotherapy for NMIBC, yet it suffers from limited efficacy, frequent tumor recurrence, and substantial toxicity. These limitations underscore the need for safer, more effective, and accessible alternatives. We investigated whether uropathogenic

Indexed as

BCG VaccineImmunotherapyUrinary Bladder NeoplasmsUropathogenic Escherichia coliAnimalsCell Line, TumorFemaleHumansMiceNon-Muscle Invasive Bladder NeoplasmsRatsBCG VaccineBCGbladder cancer

Identifiers

PMID41677596
PMCPMC12897334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.